OncoMatch/Clinical Trials/NCT04616209
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Is NCT04616209 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies donor-derived NK cell infusion for non-small cell lung cancer.
Treatment: donor-derived NK cell infusion — Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiation therapy to the lung fields
Patients who have had radiation to the lung fields within four weeks of starting treatment
Lab requirements
Blood counts
ANC ≥ 1500 cells/mm3; Platelet count ≥ 75,000 cells/mm3; Hgb ≥ 9.0 g/dL
Kidney function
Estimated GFR ≥ 60 ml/min /1.73m2 or creatinine clearance ≥ 60 mL/min
Liver function
AST and ALT ≤ 3.0 × ULN (≤ 5× ULN if hepatic metastases); total serum bilirubin ≤ 1.5 × ULN
Acceptable organ function, as evidenced by the following laboratory data: (a) AST and ALT ≤ 3.0 × ULN (≤ 5× ULN if hepatic metastases) (b) Total serum bilirubin ≤ 1.5 × ULN (c) ANC ≥ 1500 cells/mm3 (d) Platelet count ≥ 75,000 cells/mm3 (e) Hgb ≥ 9.0 g/dL (f) Estimated GFR ≥ 60 ml/min /1.73m2 or creatinine clearance ≥ 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04616209 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy to the lung fields disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIIB or IV is required.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 20 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages